News & Analysis on Clinical Trial Services & Contract Research And Development
The group whose comments on sponsor oversight drew criticism from ACRO says the industry group's preferred ‘trust and verify’ model only works if verification efforts are robust.
AMRI says the decision to close its second discovery services facility in a year and shift work to Asia reflects changing market demand.
Ranbaxy has predicted ‘market disruption’ after quality problems forced it to halt production of its generic version of Pfizer’s cholesterol buster Lipitor.
The USP says a new nomenclature scheme for salt drug substances will make for consistent product naming and ultimately help drugmakers.